Please login to the form below

Not currently logged in
Email:
Password:

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

Gilead Sciences has responded to its growing pharma business in infectious diseases with two senior appointments.

Dr Andrew Cheng has been promoted from his current role as senior VP, HIV therapeutics and development operations to an executive VP position.

Similarly Dr Taiyin Yang is promoted from senior VP to executive VP with responsibility for pharmaceutical development and manufacturing.

Norbert Bischofberger, the company's chief scientific officer, said: “Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly.

“These promotions recognise their achievements and dedication to bringing innovative new therapies to patients around the world.”

Dr Cheng has been with Gilead since 1999 and was appointed to his senior VP role in 2009.

Dr Yang is also a veteran of the company having joined in 1993. She was appointed senior VP in 2005.

4th February 2015

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics